United States Patent 5,643,607: Scope, Claim Construction, and US Patent Landscape
US Patent 5,643,607 claims microcapsules and manufacturing processes for zero-order release of an LH-RH (GnRH) analog over multi-month durations, using a specific lactic acid homopolymer defined by molecular-weight and dispersion parameters. The claim set is structured to lock both the product composition (microcapsule architecture and polymer specification) and the manufacture method (water-in-oil emulsion parameters and microencapsulation or in-water drying/phase-separation) to achieve sustained release.
What is the core claim scope in US 5,643,607?
Claim 1 (product): microcapsule + zero-order release + polymer specification + emulsion parameterization
Claim 1 is the independent claim. It requires all of the following elements:
- Product: “A microcapsule exhibiting zero order release” of an LH-RH analog
- Duration: “for a period of at least two months upon administration”
- Preparation method (structural tie to composition):
- Form a water-in-oil emulsion with:
- Inner aqueous phase that is “free from a drug retaining substance” and contains 35 to 60% (W/W) LH-RH analog
- Oil phase that contains a homopolymer of lactic acid with:
- Weight-average molecular weight (Mw): 14,100 to 18,200
- Dispersion degree (Mw/Mn): 1.5 to 2.5
- Use that emulsion as material for forming an outer wall
- Then “subjecting said water-in-oil emulsion to microencapsulation”
Claim 1 is therefore not a generic sustained-release GnRH implant. It is constrained to a microcapsule whose outer wall material is a lactic acid homopolymer with narrowly defined Mw and polydispersity (Mw/Mn), and whose drug loading in the inner aqueous phase is 35–60% by weight, while also requiring absence of any drug retaining substance in that inner phase.
Claim 2 (product): extended duration
Claim 2 depends from claim 1 and increases the duration requirement:
- Zero-order release for at least three months
This narrows scope to microcapsules meeting claim 1’s composition parameters and also achieving a longer release profile.
Claim 3 (product): polymer concentration range in oil
Claim 3 depends from claim 1 and specifies:
- Concentration of lactic acid homopolymer in the oil phase is 2 to 60% by weight
This limits the emulsion formulation window that defines the final outer-wall composition.
Claim 4 (product): drug identity / molecular weight threshold
Claim 4 depends from claim 1 and narrows the LH-RH analog to:
- Water-soluble
- Molecular weight ≥ 1,000
It does not require a specific sequence or salt form at this point, but it excludes lower-MW and non-water-soluble analogs from the claimed subject matter.
What is the process scope in US 5,643,607?
Claim 5 (process): emulsion + polymer specification + in-water drying/phase separation
Claim 5 is the independent process claim. It requires producing a microcapsule with zero-order release for at least two months by:
- Preparing a water-in-oil emulsion with the same constrained parameters as claim 1:
- Inner aqueous phase:
- free from a drug retaining substance
- contains 35 to 60% (W/W) LH-RH analog
- Oil phase:
- contains lactic acid homopolymer with:
- Mw 14,100 to 18,200
- Mw/Mn (dispersion degree) 1.5 to 2.5
- Forming the outer wall material from that emulsion
- Subjecting the emulsion to either of:
- in-water drying, or
- phase-separation
This claim ties the same polymer and loading parameters to a specific manufacturing route that is different from claim 1’s “microencapsulation” wording.
Claim 6 (process): ternary emulsion + in-water drying
Claim 6 depends from claim 5 and requires:
- Disperse water-in-oil emulsion in an aqueous phase
- Form a water/oil/water ternary emulsion
- Subject ternary emulsion to in-water drying
Claim 7 (process): emulsifier addition
Claim 7 depends from claim 5 and specifies:
- Aqueous phase contains polyvinyl alcohol as emulsifying agent
Claim 8 (process): drug identity / solubility and MW
Claim 8 depends from claim 5 and requires:
- LH-RH analog is water-soluble
- Molecular weight ≥ 1,000
Claim 9 (process): specific LH-RH analog
Claim 9 depends from claim 5 and specifies LH-RH analog identity as:
- (pyr)Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5
This is a concrete peptide sequence ending in an ethylcarboxamide motif (“NHC2H5”).
Where is the claim scope most vulnerable or most enforceable?
Most enforceable constraints
The strongest, likely-to-be-enforceable constraints are the ones that are both:
- objective/technical (measurable), and
- central to the claim language.
Key “hard stops” include:
- Drug loading in inner aqueous phase: 35–60% W/W
- No drug retaining substance in inner aqueous phase
- Outer wall polymer defined by two parameters:
- Mw 14,100–18,200
- Dispersion degree Mw/Mn 1.5–2.5
- Zero-order release duration thresholds: ≥2 months (independent) and ≥3 months (dependent)
These are not generic “PLLA” claims; they are PLLA (lactic acid homopolymer) constrained by Mw and dispersity, plus formulation/loading constraints.
Most vulnerable constraints
Potential vulnerability comes from ambiguity or non-core interpretation issues:
- “Zero order release” is an expected pharmacotechnical profile, but its implementation can be challenged on measurement method, assay timing, and definition.
- “Free from a drug retaining substance” can become a dispute over what counts as a “drug retaining substance,” depending on formulation components, excipients, and trace constituents.
- “Microencapsulation” in claim 1 is broad relative to claim 5’s “in-water drying or phase-separation.” If manufacturing uses alternative steps, claim mapping may turn on whether the step is “microencapsulation” in the ordinary patent sense.
Practical claim chart: mapping elements likely to determine infringement
| Claim element |
Required limitation |
Infringement trigger in practice |
| Microcapsule |
Microcapsule exhibiting zero-order release of LH-RH analog |
Product must show sustained, near zero-order release |
| Duration |
≥2 months (claim 1,5,8,9) or ≥3 months (claim 2) |
Release testing duration threshold |
| Inner aqueous phase |
Free from drug retaining substance + 35–60% W/W LH-RH analog |
Formulation must match drug loading window and absence of drug-retainer category |
| Oil phase / outer wall polymer |
lactic acid homopolymer, Mw 14,100–18,200, Mw/Mn 1.5–2.5 |
Polymer must match both molecular weight and dispersity specs |
| Outer wall formation |
Use emulsion as material for outer wall + microencapsulation (claim 1) or in-water drying/phase separation (claim 5) |
Process must use claimed manufacturing approach |
| Emulsion formulation concentration |
2–60% w/w polymer in oil (claim 3) |
Formulation must fall inside range |
| Drug identity |
water-soluble and MW ≥1000 (claims 4,8) |
Excludes some analogs; includes peptide analogs above threshold |
| Specific peptide |
(pyr)Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 (claim 9) |
Requires identity match to that analog |
How does US 5,643,607 sit in the US patent landscape?
Positioning relative to common GnRH depot strategies
In the US, GnRH depot technologies typically cluster around:
- polymer matrices and microspheres (often polylactide/polyglycolide families),
- biodegradable implantables and injectables with sustained pharmacokinetics,
- formulation-driven release modulation by polymer molecular weight, ratio, and particle architecture.
US 5,643,607 occupies a narrower slice:
- It is specifically directed to microcapsules with zero-order release and a polymer defined by numeric Mw and dispersity, not just “PLLA” generally.
- It also requires a specific high drug loading window (35–60% by weight) in the inner aqueous phase.
That combination narrows the set of designs that plausibly fall within claim scope, but it gives a clearer “design-around” path for competitors: vary polymer Mw/dispersity, drug loading, or the “free from drug retaining substance” condition, or change manufacturing steps away from the claimed emulsion-to-microcapsule processes.
Competitive relevance
The claims read like they are designed to capture:
- microsphere-like systems made from biodegradable lactide homopolymers,
- with manufacturing that uses emulsion and microencapsulation methods,
- where drug is dissolved at high concentration in the inner aqueous phase and then encapsulated.
Companies developing GnRH depots using biodegradable polymers likely face two risk bands:
- High risk if they use lactic acid homopolymer in the stated Mw/polydispersity window and similar drug loading in inner aqueous phase.
- Lower risk if they use different polymer grade specs (Mw and Mw/Mn), different loading logic, or different encapsulation route (e.g., different wall-forming chemistry or different encapsulation apparatus/process).
Claim coverage map by design dimension (what competitors can change)
1) Polymer selection and grade
The claim requires “homopolymer of lactic acid” with:
- Mw 14,100–18,200
- Mw/Mn 1.5–2.5
A design-around typically focuses on changing:
- Mw outside the range (lower or higher),
- dispersity outside 1.5–2.5,
- or using copolymers instead of a homopolymer (if not within literal scope).
2) Drug loading in inner aqueous phase
Claim requires:
- inner aqueous phase drug concentration 35–60% W/W
- and “free from a drug retaining substance”
Design-around directions:
- shift loading outside 35–60% W/W,
- introduce a component that arguably qualifies as a “drug retaining substance” (to avoid “free from”),
- or dissolve drug differently (though solubility may constrain the feasibility).
3) Manufacturing route
- Claim 1: “subjecting said water-in-oil emulsion to microencapsulation”
- Claim 5: “in-water drying or phase-separation” after outer-wall formation
A competitor manufacturing with different emulsion handling and wall solidification steps may reduce literal alignment with claim 5, though doctrine-of-equivalents arguments are case-specific.
4) Release target definition
Both independent and dependent claims recite “zero order release” plus durations.
If a competitor produces a depot with non-zero-order kinetics or different release duration, claim alignment can fail even if composition and polymer specs match.
Key Takeaways
- US 5,643,607 is a targeted microcapsule patent for GnRH (LH-RH) analogs with zero-order release lasting ≥2 months (and ≥3 months in a dependent claim).
- Literal claim scope turns on four technical “gates”:
1) inner aqueous phase drug concentration (35–60% W/W), and its absence of drug retaining substance,
2) outer wall polymer specs: lact lactic acid homopolymer with Mw 14,100–18,200 and Mw/Mn 1.5–2.5,
3) the process architecture (microencapsulation vs in-water drying/phase separation),
4) release kinetics and duration (“zero order release” for the stated periods).
- For landscape and freedom-to-operate, the most actionable risk variable is whether a candidate depot uses PLLA (or lactic acid homopolymer) grade specs that match both Mw and dispersity, not just generic lactide homopolymers.
- The most direct design-around levers are to move polymer Mw/polydispersity, adjust inner aqueous drug loading, or change the emulsion-to-wall solidification step away from the claimed methods.
FAQs
1) Do the claims cover all lactide-based polymers?
No. They require a lactic acid homopolymer with Mw 14,100–18,200 and dispersion degree Mw/Mn 1.5–2.5.
2) Is “zero-order release” the only release-related limitation?
No. It is paired with duration thresholds: ≥2 months in independent claims and ≥3 months in claim 2.
3) What is the significance of “inner aqueous phase free from a drug retaining substance”?
It is a literal formulation constraint. The claim excludes inner aqueous phases that include a “drug retaining substance” as that term is construed during infringement analysis.
4) Does claim coverage extend to specific GnRH sequences?
Yes. Claim 9 covers a specific peptide: (pyr)Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5, while claims 4 and 8 cover water-soluble analogs with MW ≥1,000.
5) Which is broader: claim 1’s “microencapsulation” or claim 5’s “in-water drying or phase-separation”?
Claim 1 uses “microencapsulation,” which is not limited to in-water drying or phase-separation wording. Claim 5 is more explicitly limited to in-water drying or phase-separation steps.
References
[1] United States Patent No. 5,643,607.
